Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-ALC-1 Phase 3 Study of Brenipatide in Alcohol Use Disorder
jRCT2071250110Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of brenipatide in alcohol use disorder (AUD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in Drinking Patterns by TLFB. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on jRCT2071250110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250110.